Developing antibodies to protect against various coronaviruses
Official title: Engineering Immunity for Broad Protection Against Betacoronaviruses
Funded at Albert Einstein College of Medicine · NIH-10984676 · Data updated 2026-11-12
This study is working on developing new antibodies that can help protect people from different types of coronaviruses, including the one that causes COVID-19, by targeting a key part of the virus, so that even if the virus changes, the treatment can still work well.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $199,584 |
| NIH project number | 1K08AI180364-01A1 |
| Project ID | NIH-10984676 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of severe illness from coronaviruses, including those with underlying health conditions or those in high-exposure environments.
✕Less likely to help
Patients who are not at risk for coronavirus infections or those who have already been vaccinated with effective vaccines may not benefit from this research.
What this research studies
This research focuses on creating new antibodies that can provide broad protection against multiple types of coronaviruses, including those that have caused significant outbreaks like SARS-CoV-2. The approach involves identifying and designing antibodies that target a specific part of the virus known as the spike protein, which is crucial for the virus to enter human cells. By using various laboratory techniques, the researchers will assess how effective these antibodies are in neutralizing the virus and activating the immune response. This work aims to develop therapies that remain effective even as the virus mutates.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines and treatments for current and future coronavirus infections.
How similar studies have gone: Previous research has shown promise in developing broadly acting antibodies for viral infections, indicating potential success for this novel approach.
Where this research is happening
-
Albert Einstein College of Medicine
Bronx, United States Active
Researchers
- Principal investigator: Miller, Emily Happy — Albert Einstein College of Medicine
- Study coordinator: Miller, Emily Happy
Related research
Other NIH-funded projects on the same topics.
-
Participatory system dynamics to improve PrEP access in the Bronx
A community-driven project in the Bronx will use system dynamics to identify practical ways to help people at risk for HIV start and stay on PrEP.
-
Collaborative research network program for advancements in health science
A NIH-funded multi-institution project aims to advance health science through coordinated research efforts over five years for potential patient benefits.
-
Collaborative NIH Initiative to Advance Health
A national team project aims to make progress in a broad health area with potential benefits for patients.
-
A decentralized, post-incarceration program to help people living with or at risk for HIV
A patient-facing program called DEST2nation aims to help people recently released from jail or prison stay on HIV treatment (ART) and prevention (PrEP) by coordinating care, housing, and support services through peers and community organizations.
-
Project-002: a patient-facing look at a multi-institution effort
A concise, patient-friendly overview of a multi-site NIH project that may explore new approaches to health care over several years.
-
Plug-and-play vaccine and antibody blueprints for emerging flu-like viruses
A multi-team NIH grant aims to create adaptable vaccine and antibody blueprints to rapidly respond to new enveloped RNA viruses in three families.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.